Skip Navigation


Collaborator Funding and Acknowledgements for Phase 2

(study acronyms/abbreviations are listed in Participating Studies)


List of sponsors




National Health and Medical Research Council of Australia program grant 571281; Servier


KAKENHI (09470112, 13470087, 17390185, 18590594, 20590641, 20790438, 22390133)


Canadian Institutes of Health Research; Alberta Innovates - Health Solutions; Kidney Foundation of Canada


The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions.


The Baker IDI Heart and Diabetes Institute, Melbourne, Australia, their sponsors, and the National Health and Medical Research Council of Australia (NHMRC grant 233200), Amgen Australia, Kidney Health Australia and The Royal Prince Alfred Hospital, Sydney, Australia.

BC Cohort

BC Provincial Renal Agency, an Agency of the Provincial Health Services Authority in collaboration with University of British Columbia.

Beaver Dam

NIH/NEI  EY 006594


The research for this study was supported by the Program for New Century Excellent Talents in University (BMU2009131) from the Ministry of Education of the People’s Republic of China, and the grants for the Early Detection and Prevention of Non-communicable Chronic Diseases from the International Society of Nephrology Research Committee.


Alberta Heritage Foundation for Medical Research/Alberta Innovates Health Solutions Interdisciplinary Team Grants Program


The research reported in this article was supported by contracts HHSN268201200036C, N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at


Wellcome Trust, UK


British Renal Society Project Grant Award

British Heart Foundation Project Grant Award.


Ministry of Research, Science and the Arts Baden-Württemberg (Stuttgart, Germany), Federal Ministry of Education and Research (Berlin, Germany), Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany), European Commission FP7 framework programme of DG-Research (CHANCES Project). Measurement of urinary albumin was funded by Dade-Behring, Marburg, Germany.


NHLBI Framingham Heart Study (N01-HC-25195).


Geisinger Clinic


Chief Scientist Office CZH/4/656


Municipal and Health Authorities of Gubbio, Italy; Federico II University, Naples, Italy; University of Milan, Milan, Italy; Istituto Superiore di Sanità, Rome, Italy; Northwestern University, Chicago, USA; University of Salerno, Italy; Merck Sharp & Dohme – Italy.




The MASTERPLAN study is a clinical trial with trial registration ISRCTN registry: 73187232. Sources of funding: The MASTERPLAN Study was supported by grants from the Dutch Kidney Foundation (Nierstichting Nederland, number PV 01), and the Netherlands Heart Foundation (Nederlandse Hartstichting, number 2003 B261). Unrestricted grants were provided by Amgen, Genzyme, Pfizer and Sanofi-Aventis.


NIDDK UO1 DK35073 and K23 DK67303, K23 DK02904


This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute.  The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions.  A full list of participating MESA investigators and institutions can be found at


The MMKD study was funded by the Austrian Heart Fund and by the Innsbruck Medical University.

MRC Older People

UK Medical Research Council, Department of Health for England, Wales and the Scottish Office and Kidney Research UK


The Multiple Risk Factor Intervention Trial was contracted by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Md.  Follow-up after the end of the trial was supported with NIH/NHLBI grants R01-HL-43232 and R01-HL-68140.  The principal investigators and senior staff of the clinical centers, coordinating center, other support centers and key committees are listed in a previous report (JAMA 1982; 248: 1465-1477).


United States Center for Disease Control


The NephroTest CKD cohort study is supported by grants from: Inserm GIS-IReSP AO 8113LS TGIR; French Ministry of Health AOM 09114 and AOM 10245; Inserm AO 8022LS; Agence de la Biomédecine R0 8156LL, AURA, and Roche 2009-152-447G. The Nephrotest initiative was also sponsored by unrestricted grants from F.Hoffman-La Roche Ltd.

The authors thank the collaborators and the staff of the NephroTest Study: Gauci C, Karras A, Maruani G, Daugas E, d'Auzac C, Jacquot C, Thervet E, Roland M, Letavernier E, Boffa JJ, Ronco P, Fessi H, du Halgouet C, Vrtovsnik F, Urena P.


Grant-in-Aid(H20-22Junkankitou[Seishuu]-Ippan-009, 013 and H23-Junkankitou [Senshuu]-Ippan-005) from the Ministry of Health, Labor and Welfare, Health and Labor Sciences Research Grants, Japan; Japan Atherosclerosis Prevention Fund.


This work was by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases


The PREVEND study is supported by several grants from the Dutch Kidney Foundation, and grants from the Dutch Heart Foundation, the Dutch Government (NWO), the US National Institutes of Health (NIH) and the University Medical Center Groningen, The Netherlands (UMCG). Dade Behring, Marburg, Germany supplied equipment and reagents for nephelometric measurement of urinary albumin.

Rancho Bernardo

NIA AG07181 and AG028507 NIDDK DK31801


This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis or interpretation of the data. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions.  A full list of participating REGARDS investigators and institutions can be found at

Additional funding was provided by an investigator-initiated grant-in-aid from Amgen.  Representatives from Amgen did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. 


The RENAAL trial was supported by Merck and Company.


Seoul city R&BD program (10526), Korea, The National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (1220180), and The National Research Foundation of Korea(NRF) grant funded by the Korea government(MEST) (2011-0029348).


This study was supported by Taiwan Department of Health Clinical Trial and Research Centre of Excellence (DOH 101-TD-B-111-004)


The Swedish Research Council (2006-6555), the Swedish Heart-Lung Foundation, Dalarna University, and Uppsala University.


© , Johns Hopkins University. All rights reserved.
Web policies, 615 N. Wolfe Street, Baltimore, MD 21205